RNS out today..8 Dec 2022 07:06
...all going to plan, plenty cash in bank... nice.
The very substantial out-licensing deal with STALICLA extends the application of SFX-01 into neurodevelopmental disorders, both reducing Evgen's risk profile and potentially providing substantial non-dilutive cash receipts.
The Board would like to thank all our shareholders for their support and look forward to progressing the Company's strategy which remains clearly focused on commercialising the undoubted potential of SFX-01.